Swiss Life Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Swiss Life Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,543	Closed	-$239K	–	1670
2026 Q1	$239K	Buy	16,543 +3,786	+30%	+$54.3K	﹤0.01%	1272
2025 Q4	$182K	Buy	12,757 +2,230	+21%	+$21.9K	﹤0.01%	1308
2025 Q3	$83K	Buy	+10,527	New	+$74.9K	﹤0.01%	1160

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Swiss Life Asset Management's FOLD Position: Q2 2026 in Review

Swiss Life Asset Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 16,543 shares — an estimated $239K sold.

Swiss Life Asset Management first reported a position in FOLD in Q3 2025 and held it in 3 quarters. The position peaked at $239K in Q1 2026. 1 fund tracked by Wall St. Rank holds FOLD as of Q2 2026.

Swiss Life Asset Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Swiss Life Asset Management sold 16,543 Amicus Therapeutics shares in Q2 2026, an estimated $239K.
Swiss Life Asset Management first reported a position in Amicus Therapeutics in Q3 2025 and held it in 3 quarters.
Swiss Life Asset Management's Amicus Therapeutics position peaked at $239K in Q1 2026.
1 fund tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.